Sale!

Oncopro Comprehensive Cancer Panel 161 Genes Test Cost

Original price was: 11,200 د.إ.Current price is: 8,400 د.إ.

-25%

The Oncopro Comprehensive Cancer Panel 161 Genes Test, available at DNA Labs UAE, is a sophisticated diagnostic tool designed to offer a detailed genetic analysis relevant to a wide range of cancers. Priced at 8400 AED, this test screens for mutations in 161 genes associated with increased cancer risk, aiding in the early detection and personalized treatment planning for patients. By analyzing an individual’s genetic makeup, healthcare professionals can identify specific genetic mutations that may contribute to the development and progression of cancer. This information is crucial for crafting targeted therapy plans, making risk assessments, and implementing preventive measures for individuals at heightened risk. Conducted in the advanced facilities of DNA Labs UAE, this comprehensive panel is a pivotal step towards personalized medicine in oncology, offering hope for more effective and tailored cancer care strategies.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

ONCOPRO COMPREHENSIVE CANCER PANEL 161 GENES Test

Test Name: ONCOPRO COMPREHENSIVE CANCER PANEL 161 GENES Test

Components:

  • 86 Hotspot genes
  • 47 full length genes
  • Copy number variations in 43 genes
  • Fusions in 48 genes

Price: 8400.0 AED

Sample Condition: Submit formalin fixed paraffin embedded (FFPE) tissue block. Ship at room temperature. Block should have at least 10% tumor tissue.

Report Delivery: Sample Daily by 11 am; Report 35 Working days

Method: Next Generation Sequencing

Test Type: Cancer

Doctor: Oncologist

Test Department: MOLECULAR DIAGNOSTICS

Pre Test Information: Block should have at least 10% tumor tissue.

Test Details:

The ONCOPRO Comprehensive Cancer Panel is a genetic test that analyzes 161 genes associated with various types of cancer. The test uses next-generation sequencing technology to identify mutations and other genetic alterations that may contribute to the development and progression of cancer. The genes included in the panel are selected based on their known association with cancer, including genes involved in cell growth and division, DNA repair, and tumor suppression.

The test can detect a range of genetic alterations, including single nucleotide variants, small insertions and deletions, copy number changes, and gene fusions. The ONCOPRO Comprehensive Cancer Panel is used to help diagnose cancer, determine prognosis, and guide treatment decisions. The test can identify specific mutations that may be targeted by certain cancer therapies, and can also help identify patients who may be at increased risk for certain types of cancer based on their genetic profile.

The test is typically performed on a tumor sample, but can also be performed on blood or other tissue samples. Results are typically available within a few weeks and are reported in a detailed clinical report that includes information on any identified mutations, their clinical significance, and potential treatment options.

Test Name ONCOPRO COMPREHENSIVE CANCER PANEL 161 GENES Test
Components *86 Hotspot genes*47 full length genes*Copy number variations in 43 genes*Fusions in 48 genes
Price 8400.0 AED
Sample Condition Submit formalin fixed paraffin embedded (FFPE) tissue block.Ship at room temperature. Block should have atleast 10% tumor tissue.
Report Delivery Sample Daily by 11 am; Report 35 Working days
Method Next Generation Sequencing
Test type Cancer
Doctor Oncologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information Block should have atleast 10% tumor tissue.
Test Details

The ONCOPRO Comprehensive Cancer Panel is a genetic test that analyzes 161 genes associated with various types of cancer. The test uses next-generation sequencing technology to identify mutations and other genetic alterations that may contribute to the development and progression of cancer.

The genes included in the panel are selected based on their known association with cancer, including genes involved in cell growth and division, DNA repair, and tumor suppression. The test can detect a range of genetic alterations, including single nucleotide variants, small insertions and deletions, copy number changes, and gene fusions.

The ONCOPRO Comprehensive Cancer Panel is used to help diagnose cancer, determine prognosis, and guide treatment decisions. The test can identify specific mutations that may be targeted by certain cancer therapies, and can also help identify patients who may be at increased risk for certain types of cancer based on their genetic profile.

The test is typically performed on a tumor sample, but can also be performed on blood or other tissue samples. Results are typically available within a few weeks and are reported in a detailed clinical report that includes information on any identified mutations, their clinical significance, and potential treatment options.